S&P 500   3,294.75 (+0.42%)
DOW   27,193.94 (+0.17%)
QQQ   268.67 (+0.43%)
AAPL   111.24 (+1.05%)
MSFT   203.89 (+0.67%)
FB   249.77 (+0.65%)
GOOGL   1,443.60 (+0.94%)
AMZN   3,045.00 (+2.86%)
NVDA   489.17 (-2.30%)
TSLA   431.46 (-3.99%)
BABA   272.85 (-0.35%)
CGC   15.63 (-0.70%)
GE   6.38 (+0.47%)
MU   49.34 (+0.39%)
AMD   75.97 (-2.53%)
T   28.68 (+0.17%)
F   6.90 (+0.44%)
ACB   6.40 (+1.27%)
GILD   63.87 (-0.53%)
NFLX   485.92 (-0.29%)
DIS   125.84 (+0.34%)
BAC   24.26 (-0.86%)
BA   157.81 (+0.93%)
S&P 500   3,294.75 (+0.42%)
DOW   27,193.94 (+0.17%)
QQQ   268.67 (+0.43%)
AAPL   111.24 (+1.05%)
MSFT   203.89 (+0.67%)
FB   249.77 (+0.65%)
GOOGL   1,443.60 (+0.94%)
AMZN   3,045.00 (+2.86%)
NVDA   489.17 (-2.30%)
TSLA   431.46 (-3.99%)
BABA   272.85 (-0.35%)
CGC   15.63 (-0.70%)
GE   6.38 (+0.47%)
MU   49.34 (+0.39%)
AMD   75.97 (-2.53%)
T   28.68 (+0.17%)
F   6.90 (+0.44%)
ACB   6.40 (+1.27%)
GILD   63.87 (-0.53%)
NFLX   485.92 (-0.29%)
DIS   125.84 (+0.34%)
BAC   24.26 (-0.86%)
BA   157.81 (+0.93%)
S&P 500   3,294.75 (+0.42%)
DOW   27,193.94 (+0.17%)
QQQ   268.67 (+0.43%)
AAPL   111.24 (+1.05%)
MSFT   203.89 (+0.67%)
FB   249.77 (+0.65%)
GOOGL   1,443.60 (+0.94%)
AMZN   3,045.00 (+2.86%)
NVDA   489.17 (-2.30%)
TSLA   431.46 (-3.99%)
BABA   272.85 (-0.35%)
CGC   15.63 (-0.70%)
GE   6.38 (+0.47%)
MU   49.34 (+0.39%)
AMD   75.97 (-2.53%)
T   28.68 (+0.17%)
F   6.90 (+0.44%)
ACB   6.40 (+1.27%)
GILD   63.87 (-0.53%)
NFLX   485.92 (-0.29%)
DIS   125.84 (+0.34%)
BAC   24.26 (-0.86%)
BA   157.81 (+0.93%)
S&P 500   3,294.75 (+0.42%)
DOW   27,193.94 (+0.17%)
QQQ   268.67 (+0.43%)
AAPL   111.24 (+1.05%)
MSFT   203.89 (+0.67%)
FB   249.77 (+0.65%)
GOOGL   1,443.60 (+0.94%)
AMZN   3,045.00 (+2.86%)
NVDA   489.17 (-2.30%)
TSLA   431.46 (-3.99%)
BABA   272.85 (-0.35%)
CGC   15.63 (-0.70%)
GE   6.38 (+0.47%)
MU   49.34 (+0.39%)
AMD   75.97 (-2.53%)
T   28.68 (+0.17%)
F   6.90 (+0.44%)
ACB   6.40 (+1.27%)
GILD   63.87 (-0.53%)
NFLX   485.92 (-0.29%)
DIS   125.84 (+0.34%)
BAC   24.26 (-0.86%)
BA   157.81 (+0.93%)
Log in
NASDAQ:FMTX

Forma Therapeutics Stock Forecast, Price & News

$44.41
+0.72 (+1.65 %)
(As of 09/22/2020 10:00 AM ET)
Add
Compare
Today's Range
$44.41
Now: $44.41
$44.80
50-Day Range
$32.95
MA: $39.56
$47.33
52-Week Range
$31.45
Now: $44.41
$50.00
Volume191 shs
Average Volume199,126 shs
Market Capitalization$1.83 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FMTX
CUSIPN/A
CIKN/A
Phone617-679-1970

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$100.56 million

Profitability

Miscellaneous

Employees77
Market Cap$1.83 billion
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$44.41
+0.72 (+1.65 %)
(As of 09/22/2020 10:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for FMTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Forma Therapeutics (NASDAQ:FMTX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Forma Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Forma Therapeutics
.

When is Forma Therapeutics' next earnings date?

Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Forma Therapeutics
.

How were Forma Therapeutics' earnings last quarter?

Forma Therapeutics Holdings Inc (NASDAQ:FMTX) announced its quarterly earnings results on Thursday, August, 13th. The company reported ($4.58) EPS for the quarter, missing the consensus estimate of ($0.74) by $3.85.
View Forma Therapeutics' earnings history
.

What price target have analysts set for FMTX?

4 Wall Street analysts have issued 1-year price targets for Forma Therapeutics' stock. Their forecasts range from $53.00 to $64.00. On average, they expect Forma Therapeutics' share price to reach $56.25 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price.
View analysts' price targets for Forma Therapeutics
.

Who are some of Forma Therapeutics' key competitors?

What other stocks do shareholders of Forma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Trade Desk (TTD), Boeing (BA), NVIDIA (NVDA), Okta (OKTA), Abbott Laboratories (ABT), Alibaba Group (BABA), CVS Health (CVS), Walt Disney (DIS), Gilead Sciences (GILD) and General Motors (GM).

Who are Forma Therapeutics' key executives?

Forma Therapeutics' management team includes the following people:
  • Mr. Frank D. Lee, Pres, CEO & Director (Age 52)
  • Mr. Todd E. Shegog, Sr. VP & CFO (Age 55)
  • Dr. David N. Cook, Sr. VP & Chief Scientific Officer (Age 62)
  • Dr. Jeannette Potts J.D., Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 58)
  • Ms. Mary E. Wadlinger, Sr. VP of Corp. Affairs & Chief HR Officer (Age 60)

When did Forma Therapeutics IPO?

(FMTX) raised $201 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 11,800,000 shares at $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO.

What is Forma Therapeutics' stock symbol?

Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX."

When does the company's lock-up period expire?

Forma Therapeutics' lock-up period expires on Wednesday, December 16th. Forma Therapeutics had issued 13,882,352 shares in its IPO on June 19th. The total size of the offering was $277,647,040 based on an initial share price of $20.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Forma Therapeutics' major shareholders?

Forma Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (8.66%), FMR LLC (4.34%), Logos Global Management LP (3.28%), Perceptive Advisors LLC (3.20%), Hillhouse Capital Advisors LTD. (1.28%) and Goldman Sachs Group Inc. (0.25%).

Which institutional investors are buying Forma Therapeutics stock?

FMTX stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, FMR LLC, Logos Global Management LP, Perceptive Advisors LLC, Hillhouse Capital Advisors LTD., Goldman Sachs Group Inc., Jane Street Group LLC, and Alyeska Investment Group L.P..

How do I buy shares of Forma Therapeutics?

Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Forma Therapeutics' stock price today?

One share of FMTX stock can currently be purchased for approximately $44.41.

How big of a company is Forma Therapeutics?

Forma Therapeutics has a market capitalization of $1.83 billion and generates $100.56 million in revenue each year. Forma Therapeutics employs 77 workers across the globe.

What is Forma Therapeutics' official website?

The official website for Forma Therapeutics is www.formatherapeutics.com.

How can I contact Forma Therapeutics?

Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The company can be reached via phone at 617-679-1970 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.